市場調査レポート

商品コード

1116915

難治性慢性咳嗽市場 - 市場の洞察、疫学、市場予測：2032年

Chronic Refractory Cough - Market Insight, Epidemiology And Market Forecast - 2032

出版日: 2022年08月01日 | 発行: DelveInsight

| ページ情報: 英文 155 Pages | 納期: 1～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 7,500 1,165,950円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Site License)

USD 15,000 2,331,900円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。ご利用人数の制限はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Global License)

USD 22,500 3,497,850円

レポートPDFを同一企業の全世界の方にご利用頂けるライセンスです。ご利用人数に制限はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.46円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

主要7ヶ国における難治性慢性咳嗽の市場規模は、2021年に87億4,020万米ドルになるとみられています。

当レポートでは、主要7ヶ国における難治性慢性咳嗽市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2032年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

主な調査結果
難治性慢性咳嗽市場の調査手法
主要7ヶ国における難治性慢性咳嗽の市場規模
主要7ヶ国における難治性慢性咳嗽の市場規模、治療法別
主要な市場予測の前提条件
属性分析
市場の見通し
米国における難治性慢性咳嗽の市場規模
欧州5ヶ国における難治性慢性咳嗽の市場規模
日本における難治性慢性咳嗽の市場規模

第12章キーオピニオンリーダーの見解

第13章市場の促進要因

第14章市場の抑制要因

第15章 SWOT分析

第16章アンメットニーズ

第17章償還と市場アクセス

第18章付録

第19章 DelveInsightのサービス内容

第20章免責事項

第21章 Delve Insightについて

図表

List of Tables

Table 1: Summary of CRC, Market, Epidemiology, and Key Events (2019-2032)
Table 2: Key Events
Table 3: Recommendations, strength and level of evidence, and supporting remarks for the diagnosis and treatment of CC in adults and children
Table 4: Comparison of cough guidelines in relation to CRC
Table 5: 12-month Prevalent Cases of CC in the 7MM, in Thousands (2019-2032)
Table 6: Total Diagnosed Prevalent Cases of CRC in the 7MM, in Thousands (2019-2032)
Table 7: 12-month Prevalent Cases of CC in the US, in Thousands (2019-2032)
Table 8: Gender-specific Cases of CC in the US, in Thousands (2019-2032)
Table 9: Total Diagnosed Prevalent Cases of CRC in the US, in Thousands (2019-2032)
Table 10: Diagnosed Prevalent Cases of CC in IPF in the US, in Thousands (2019-2032)
Table 11: 12-month Prevalent Cases of CC in the EU-5, in Thousands (2019-2032)
Table 12: Gender-specific Cases of CC in the EU-5, in Thousands (2019-2032)
Table 13: Total Diagnosed Prevalent Cases of CRC in the EU-5, in Thousands (2019-2032)
Table 14: Diagnosed Prevalent Cases of CC in IPF in the EU-5, in Thousands (2019-2032)
Table 15: 12-month Prevalent Cases of CC in Germany, in Thousands (2019-2032)
Table 16: Gender-specific Cases of CC in Germany, in Thousands (2019-2032)
Table 17: Total Diagnosed Prevalent Cases of CRC in Germany, in Thousands (2019-2032)
Table 18: Diagnosed Prevalent Cases of CC in IPF in Germany, in Thousands (2019-2032)
Table 19: 12-month Prevalent Cases of CC in France, in Thousands (2019-2032)
Table 20: Gender-specific Cases of CC in France, in Thousands (2019-2032)
Table 21: Total Diagnosed Prevalent Cases of CRC in France, in Thousands (2019-2032)
Table 22: Diagnosed Prevalent Cases of CC in IPF in France, in Thousands (2019-2032)
Table 23: 12-month Prevalent Cases of CC in Italy, in Thousands (2019-2032)
Table 24: Gender-specific Cases of CC in Italy, in Thousands (2019-2032)
Table 25: Total Diagnosed Prevalent Cases of CRC in Italy, in Thousands (2019-2032)
Table 26: Diagnosed Prevalent Cases of CC in IPF in Italy, in Thousands (2019-2032)
Table 27: 12-month Prevalent Cases of CC in Spain, in Thousands (2019-2032)
Table 28: Gender-specific Cases of CC in Spain, in Thousands (2019-2032)
Table 29: Total Diagnosed Prevalent Cases of CRC in Spain, in Thousands (2019-2032)
Table 30: Diagnosed Prevalent Cases of CC in IPF in Spain, in Thousands (2019-2032)
Table 31: 12-month Prevalent Cases of CC in the UK, in Thousands (2019-2032)
Table 32: Gender-specific Cases of CC in the UK, in Thousands (2019-2032)
Table 33: Total Diagnosed Prevalent Cases of CRC in the UK, in Thousands (2019-2032)
Table 34: Diagnosed Prevalent Cases of CC in IPF in the UK, in Thousands (2019-2032)
Table 35: 12-month prevalent cases of CC in Japan, in Thousands (2019-2032)
Table 36: Gender-specific Cases of CC in Japan, in Thousands (2019-2032)
Table 37: Total Diagnosed Prevalent Cases of CRC in Japan, in Thousands (2019-2032)
Table 38: Diagnosed Prevalent Cases of CC in IPF in Japan, in Thousands (2019-2032)
Table 39: Comparison of Emerging Drugs Under Development for CRC
Table 40: MK-7264 (gefapixant), Clinical Trial Description, 2022
Table 41: Orvepitant Maleate, Clinical Trial Description, 2022
Table 42: BLU-5937, Clinical Trial Description, 2022
Table 43: S-600918 (sivopixant), Clinical Trial Description, 2022
Table 44: AX-8, Clinical Trial Description, 2022
Table 45: ADX-629, Clinical Trial Description, 2022
Table 46: Market Size of CRC in the 7MM, in USD Million (2019-2032)
Table 47: Market Size of CRC by Therapies in the 7MM, in USD Million (2019-2032)
Table 48: Key Market Forecast Assumptions for MK-7264 (gefapixant)
Table 49: Key Market Forecast Assumptions for BLU-5937
Table 50: Key Market Forecast Assumptions for S-600918
Table 51: Key Market Forecast Assumptions for Orvepitant Maleate
Table 52: Key Market Forecast Assumptions for AX-8
Table 53: Total Market Size of CRC in the US, in USD Million (2019-2032)
Table 54: Market Size of CRC by Therapies in the US, in USD Million (2019-2032)
Table 55: Total Market Size of CRC in the EU-5, in USD Million (2019-2032)
Table 56: Total Market Size of CRC in Germany, in USD Million (2019-2032)
Table 57: Market Size of CRC by Therapies in Germany, in USD Million (2019-2032)
Table 58: Total Market Size of CRC in France, in USD Million (2019-2032)
Table 59: Market Size of CRC by Therapies in France, in USD Million (2019-2032)
Table 60: Total Market Size of CRC in Italy, in USD Million (2019-2032)
Table 61: Market Size of CRC by Therapies in Italy, in USD Million (2019-2032)
Table 62: Total Market Size of CRC in Spain, in USD Million (2019-2032)
Table 63: Market Size of CRC by Therapies in Spain, in USD Million (2019-2032)
Table 64: Total Market Size of CRC in the UK, in USD Million (2019-2032)
Table 65: Market Size of CRC by Therapies in the UK, in USD Million (2019-2032)
Table 66: Market Size of CRC by Therapies in the EU-5, in USD Million (2019-2032)
Table 67: Market Size of CRC in Japan, in USD Million (2019-2032)
Table 68: Market Size of CRC by Therapies in Japan, in USD Million (2019-2032)

List of Figures

Figure 1: Symptoms of CRC
Figure 2: Origins and neurological pathways of the cough reflex.
Figure 3: A proposed algorithm detailing a management approach for the patient with a "difficult-to-treat" cough
Figure 4: 12-month Prevalent Cases of CC in the 7MM (2019-2032)
Figure 5: Total Diagnosed Prevalent Cases of CRC in the 7MM (2019-2032)
Figure 6: 12-month Prevalent Cases of CC in the US (2019-2032)
Figure 7: Gender-specific Cases of CC in the US (2019-2032)
Figure 8: Total Diagnosed Prevalent Cases of CRC in the US (2019-2032)
Figure 9: Diagnosed Prevalent Cases of CC in IPF in the US (2019-2032)
Figure 10: 12-month Prevalent Cases of CC in the EU-5 (2019-2032)
Figure 11: Gender-specific Cases of CC in the EU-5 (2019-2032)
Figure 12: Total Diagnosed Prevalent Cases of CRC in the EU-5 (2019-2032)
Figure 13: Diagnosed Prevalent Cases of CC in IPF in the EU-5 (2019-2032)
Figure 14: 12-month Prevalent Cases of CC in Germany (2019-2032)
Figure 15: Gender-specific Cases of CC in Germany (2019-2032)
Figure 16: Total Diagnosed Prevalent Cases of CRC in Germany (2019-2032)
Figure 17: Diagnosed Prevalent Cases of CC in IPF in Germany (2019-2032)
Figure 18: 12-month Prevalent Cases of CC in France (2019-2032)
Figure 19: Gender-specific Cases of CC in France (2019-2032)
Figure 20: Total Diagnosed Prevalent Cases of CRC in France (2019-2032)
Figure 21: Diagnosed Prevalent Cases of CC in IPF in France (2019-2032)
Figure 22: 12-month Prevalent Cases of CC in Italy (2019-2032)
Figure 23: Gender-specific Cases of CC in Italy (2019-2032)
Figure 24: Total Diagnosed Prevalent Cases of CRC in Italy (2019-2032)
Figure 25: Diagnosed Prevalent Cases of CC in IPF in Italy (2019-2032)
Figure 26: 12-month Prevalent Cases of CC in Spain (2019-2032)
Figure 27: Gender-specific Cases of CC in Spain (2019-2032)
Figure 28: Total Diagnosed Prevalent Cases of CRC in Spain (2019-2032)
Figure 29: Diagnosed Prevalent Cases of CC in IPF in Spain (2019-2032)
Figure 30: 12-month Prevalent Cases of CC in the UK (2019-2032)
Figure 31: Gender-specific Cases of CC in the UK (2019-2032)
Figure 32: Total Diagnosed Prevalent Cases of CRC in the UK (2019-2032)
Figure 33: Diagnosed Prevalent Cases of CC in IPF in the UK (2019-2032)
Figure 34: 12-month prevalent cases of CC in Japan (2019-2032)
Figure 35: Gender-specific Cases of CC in Japan (2019-2032)
Figure 36: Total Diagnosed Prevalent Cases of CRC in Japan (2019-2032)
Figure 37: Diagnosed Prevalent Cases of CC in IPF in Japan (2019-2032)
Figure 38: Patient Journey
Figure 39: Market Size of CRC in the 7MM (2019-2032)
Figure 40: Market Size of CRC by Therapies in the 7MM (2019-2032)
Figure 41: Total Market Size of CRC in the US (2019-2032)
Figure 42: Market Size of CRC by Therapies in the US (2019-2032)
Figure 43: Total Market Size of CRC in the EU-5 (2019-2032)
Figure 44: Market Size of CRC by Therapies in the EU-5 (2019-2032)
Figure 45: Total Market Size of CRC in Germany (2019-2032)
Figure 46: Market Size of CRC by Therapies in Germany (2019-2032)
Figure 47: Total Market Size of CRC in France (2019-2032)
Figure 48: Market Size of CRC by Therapies in France (2019-2032)
Figure 49: Total Market Size of CRC in Italy (2019-2032)
Figure 50: Market Size of CRC by Therapies in Italy (2019-2032)
Figure 51: Total Market Size of CRC in Spain (2019-2032)
Figure 52: Market Size of CRC by Therapies in Spain (2019-2032)
Figure 53: Total Market Size of CRC in the UK (2019-2032)
Figure 54: Market Size of CRC by Therapies in the UK (2019-2032)
Figure 55: Market Size of CRC in Japan (2019-2032)
Figure 56: Market Size of CRC by Therapies in Japan (2019-2032)
Figure 57: Market Drivers
Figure 58: Market Barriers
Figure 59: SWOT Analysis
Figure 60: Unmet Needs

Product Code: DIMI0626

DelveInsight's, 'Chronic Refractory Cough-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory Cough market trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Chronic Refractory Cough market report provides current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted 7MM Chronic Refractory Cough market size from 2019 to 2032. The Report also covers current Chronic Refractory Cough treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

The United States
The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019-2032

Chronic Refractory Cough Understanding and Treatment Algorithm

Chronic Refractory Cough Overview

Chronic Refractory Cough (CRC) is defined as a cough lasting more than 8 weeks despite guidelines-based treatment and which may be treated only by different medical specialties. Individuals with CRC have impaired quality of life and interruption of activities of daily living. It also results in depression and can persist for many months or years, despite systematic investigation and treatment of known causes. The infection can also be referred to as chronic cough (CC), chronic idiopathic cough (CIC), unexplained chronic cough (UCC), and cough hypersensitivity syndrome (CHS).

Recurrent incidence of CC results in CRC. The symptoms and indications of CRC are similar to those of CC. One of the first and most important symptoms that may indicate respiratory involvement is a persistent or chronic cough. Key symptoms include a dry irritated cough localized around the laryngeal region. Symptoms are not restricted to cough and can include globus, dyspnea, and dysphonia. CRC has factors in common with laryngeal hypersensitivity syndromes and chronic pain syndromes, and these similarities help to shed light on the pathophysiology of the condition.

Laryngopharyngeal reflux (LPR) is a common cause of CRC and may be present without symptoms of classic GERD, including heartburn (silent reflux). Obstructive sleep apnoea syndrome (OSAS) is also an independent risk factor for CC and a risk factor for LPR/GERD recalcitrant to medical therapy. ACE inhibitors are another common cause of CRC, which can occur spontaneously even after many years on this medication without previous problems.

CC is more prevalent in women, and there are various complications associated with it which include negative psychological, social, and physical outcomes. It causes an interruption of daily activities, social embarrassment, and physical exhaustion secondary to frequent coughing episodes.

Chronic Refractory Cough Diagnosis

CRC can be diagnosed when patients have no identified causes of CC or when the cough persists after investigation and treatment of cough-related conditions.

The diagnosis of the disease is either done by primary or secondary assessment. The initial assessment for protracted or chronic cough is intended to characterize the condition based on history, to elicit any alarm symptoms or findings that may indicate a serious underlying disease, and to identify whether there is a specific disease present that is associated with CC.

The first step in evaluating individuals with CRC is performing a correct and complete anamnesis, followed by a physical examination. While the second stage of investigation is considered to further characterize the condition of the disease. These include nasendoscopy and 24-hour pH monitoring. Laryngeal examination using flexible nasendoscopy identifies the presence of laryngeal lesions or abnormal motor patterns that might be contributing to the cough symptoms and laryngeal discomfort.

Some of the common tests that are performed to examine chronic cough are chest radiograph, spirometric and peak expiratory flow measurements, bronchoprovocation testing, sinus imaging, etc.

Continued in the report…..

Chronic Refractory Cough Treatment

According to the recent guidelines published by the American College of Chest Physicians (ACCP) four categories of treatment can be implemented which include nonpharmacologic therapies, ICS, neuromodulatory therapies, proton pump inhibitors, and other therapies.

The market for CRC is mainly dominated by nonpharmacologic therapies, which include Speech Therapy and Physiotherapy. The first step in Speech Pathology Management of CRC patients is to evaluate the pathophysiological features of the condition, including cough characteristics, urge to cough, Paradoxical vocal fold movement (PVFM), and voice symptoms.

After nonpharmacological therapies, the market holds various types of pharmacologic therapies which include neuromodulators, proton pump inhibitors, ICS, and other treatment options. Neuromodulators include opiates (morphine, codeine, tramadol, etc.), gabapentin, pregabalin, morphine, amitriptyline, and baclofen, which act on the heightened neural sensitization that is involved in the pathogenesis of CRC. Combined therapy can also be employed to treat patients with CRC. This includes the use of nonpharmacologic and pharmacologic interventions together.

Recently in 2022, Japan's MHLW approved Merck's LYNFUA (gefapixant), an orally-administered, selective P2X3 receptor antagonist for the treatment of adults with RCC or UCC.

Continued in the report…..

Chronic Refractory Cough Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by 12 month Prevalent Cases of Chronic Cough, Gender-specific Cases of Chronic Cough, Total Diagnosed Prevalent Cases of Chronic Refractory Cough, and Diagnosed Prevalent Cases of Chronic Cough in IPF scenario of Chronic Refractory Cough in the 7MM covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Key Findings

In 2021, the 12-month prevalent cases of CC were estimated to be 30,625,209 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.4% during the study period (2019-2032).
Among the 7MM, the United States accounted for nearly 42% of the 12-month prevalent cases of CC with 12,782,168 cases in 2021 which are expected to increase further by 2032.
Assessments as per DelveInsight's, analysts show that the total diagnosed prevalent cases of CRC in the 7MM were 12,250,084 cases in 2021. Among the 7MM, in 2021, the US accounted for nearly 41.7% of the total diagnosed prevalent cases of CRC. The prevalent population for CRC was derived from the prevalent patient pool of CC.
In the US, the gender-specific cases of CC were 5,061,738 and 7,720,429 cases for males and females, respectively in the year 2021, which are expected to increase by 2032.
Among the EU-5, Germany accounted for the highest number of total diagnosed prevalent cases of CRC (1,383,684), followed by Italy with 1,034,973 cases in 2021. In contrast, Spain accounted for the least of the total diagnosed prevalent cases of CRC in the EU-5.
In 2021, Japan accounted for 1,812,612 cases of total diagnosed prevalent cases of CRC, which is approximately 15% of the 7MM total diagnosed prevalent cases of CRC.
In the US, the diagnosed prevalent cases of CC in IPF were 75,537 cases in 2021 which are expected to increase by 2032.

Chronic Refractory Cough Epidemiology

The epidemiology segment also provides the Chronic Refractory Cough epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Chronic Refractory Cough Drug Chapters

The drug chapter segment of the Chronic Refractory Cough report encloses the detailed analysis of Chronic Refractory Cough marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Chronic Refractory Cough clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

Chronic Refractory Cough Emerging Drugs

MK-7264 (gefapixant): Merck & Co/ Kyorin Pharmaceuticals

MK-7264 (gefapixant), is being developed by Merck & Co for the treatment of RCC or UCC. Also known as AF-219, it is an investigational, non-narcotic, orally-administered, selective P2X3 receptor antagonist that prevents ATP binding. In 2020, Merck completed Phase III trials for MK-7264 and based on its result submitted an NDA for the approval of MK-7264. In January 2022, the FDA issued a CRL regarding Merck's NDA for MK-7264 and requested additional information related to the measurement of efficacy. Currently, Merck is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023 in response to the CRL. The review period in the EU has also been extended pending the receipt of additional information from the Company. The Company plans to submit the information to the EMA in the first half of 2023.

Products detail in the report…

BLU-5937: Bellus Health

BLU-5937 (formerly known as NEO5937), being developed by Bellus Health, is a potent, highly selective, orally bioavailable small molecule antagonist of the P2X3 receptor, a clinically validated target for CC. BLU-5937 has the potential to be a best-in-class therapeutic for CRC patients. In July 2022, Bellus Health completed an End-of-Phase II meeting with the US FDA. Based on the positive feedback from the FDA, Bellus Health plans a Phase III CALM trial consisting of two pivotal trials (CALM-1 and CALM-2), with a primary efficacy endpoint of 24-hour cough frequency measured at 12 and 24 weeks, respectively. It is expected to enroll its first patient in the fourth quarter of 2022 with topline data expected by 2024. Besides this, it also plans to initiate a Phase I clinical trial investigating a once-daily, extended-release formulation of BLU-5937.

Products detail in the report…

S-600918 (sivopixant): Shionogi

S-600918 (sivopixant) is an oral, P2X3 receptor antagonist, an antitussive agent that is being developed by Shionogi for RCC or UCC. It has high selectivity for P2X3 homomer compared with P2X2/3 heteromer, which could reduce coughs with minimal taste-related side effects. The company has already completed a Phase IIb dose-finding study and plans for Phase III trials in the future to determine a clinically optimal dose for RCC.

Products detail in the report…

AX-8: Axalbion

AX-8, being developed by Axalbion, is a potent, selective transient receptor potential melastatin 8 (TRPM8) agonist, for the treatment of CC. TRPM8 is expressed in many of the sensory fibers innervating the upper airways and can treat RCC by counterbalancing CHS by decreasing or abolishing pathological coughing, and limiting or suppressing abnormal sensations associated with cough. Recently, Axalbion announced positive Phase II results from a proof-of-concept study of AX8 in patients with RCC or UCC.

Products detail in the report…

List of products to be continued in the report…

Chronic Refractory Cough Market Outlook

CRC proves to be a huge burden on the patients who are fighting this debilitating condition. It is typically nonproductive and there is often a preceding history of viral respiratory tract infection. Patients frequently describe a dry, irritating cough that may be localized to the laryngeal region. It significantly impairs patients' quality of life. Unfortunately, in many situations, patients continue to experience CRC despite following the published guidelines for diagnosis and treatment.

Currently, the market holds no approved therapy to treat CRC. According to the recent guidelines published by the American College of Chest Physicians (ACCP) four categories of treatment can be implemented which include nonpharmacologic therapies, ICS, neuromodulatory therapies, proton pump inhibitors, and other therapies.

The market for CRC is mainly dominated by nonpharmacologic therapies, which include Speech Therapy and Physiotherapy. The main strategies that are followed by the speech therapists include education (Cough can be triggered by irritation, controlling the urge to cough, etc.), symptom control techniques, such as cough suppression swallow, cough control breathing, PVFM release breathing, and release of laryngeal restriction, reduction in laryngeal irritation (behavioral management of reflux, reduction in phonotraumatic behaviors, patients should remain hydrated and minimizing exposure to the irritating substances.

ICS are effective in eosinophilic airway inflammation. An assessment of airway eosinophilia (induced sputum, bronchoalveolar lavage) or exhaled NO is followed before subjecting patients with ICS in case of CRC. These mainly include mometasone, budesonide, and beclometasone. Treatment with ICS can significantly reduce cough but regress analyses are required to address the exact treatment regimen of these drugs.

Combined therapy can also be employed to treat patients with CRC. This includes the use of nonpharmacologic and pharmacologic interventions together, i.e., combining speech therapy with drugs to provide relief to the patients. Patients on speech therapy can be advised to opt for drugs, such as pregabalin or gabapentin. Recently Japan's MHLW approved Merck's LYNFUA (gefapixant), an orally-administered, selective P2X3 receptor antagonist for the treatment of adults with RCC or UCC

The market holds a critical unmet need with no approved curative definitive therapy for CRC. The pharmacologic therapies that are employed cannot be used in a long term due to various adverse events associated with them. Expected launch of potential therapies that include orvepitant maleate (Nerre Therapeutics), BLU-5937 (Bellus Health), MK-7264 (gefapixant) (Merck), AX-8 (Axalbion), S-600918 (Shionogi), and NP-120 (ifenprodil) (Algernon Pharmaceuticals) may address this unmet need, increase the market size in the coming years, assisted by an increase in the diagnosed prevalent population of CRC during the forecast period [2022-2032].

According to DelveInsight, the overall dynamics of the CRC market is anticipated to change in the coming years owing to the expected launch of emerging therapies.

Key Findings

The market size of Chronic Refractory Cough in the seven major markets was USD 8,740.2 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 3.9% for the study period (2019-2032).
The launch of potential therapies, MK-7264 (gefapixant), BLU-5937, S-600918 (sivopixant), AX-8, and Orvepitant Maleate is expected to increase the market size in the coming years, assisted by the increase in the diagnosed prevalent population of CRC.
The United States accounts for the largest market size for Chronic Refractory Cough, in comparison to the EU-5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
Among the EU5 countries, Germany had the highest market size with approximately USD 837.4 million in 2021. This is expected to further increase, with Germany estimated to capture the maximum market followed by the UK in 2032.
The market size for Chronic Refractory Cough in Japan was valued at approximately USD 1,097.0 million in 2021. It is expected that the market will increase mainly due to the launch of upcoming therapy during the forecast period (2022-2032).

The United States Market Outlook

This section provides the total Chronic Refractory Cough market size and market size by therapies in the United States.

The EU-5 Market Outlook

The total Chronic Refractory Cough market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Chronic Refractory Cough market size and market size by therapies in Japan are provided.

Chronic Refractory Cough Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Refractory Cough market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Chronic Refractory Cough market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Refractory Cough Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages and also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Chronic Refractory Cough emerging therapies.

Reimbursement Scenario in Chronic Refractory Cough

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitively and market Intelligence analysis of the Chronic Refractory Cough market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

The report covers the descriptive overview of Chronic Refractory Cough, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
Comprehensive insight has been provided into the Chronic Refractory Cough epidemiology and treatment.
Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Refractory Cough is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of the Chronic Refractory Cough market; historical and forecasted is included in the report, covering the 7MM drug outreach.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Chronic Refractory Cough market.

Report Highlights:

The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the Chronic Refractory Cough market.
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Refractory Cough R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Major players are involved in developing therapies for Chronic Refractory Cough. The launch of emerging therapies will significantly impact the Chronic Refractory Cough market.
Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chronic Refractory Cough Report Insights

Patient Population
Therapeutic Approaches
Chronic Refractory Cough Pipeline Analysis
Chronic Refractory Cough Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Chronic Refractory Cough Report Key Strengths

11-Years Forecast
The 7MM Coverage
Chronic Refractory Cough Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Chronic Refractory Cough Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
SWOT analysis

Key Questions

Market Insights:

What was the Chronic Refractory Cough market share (%) distribution in 2019 and how it would look like in 2032?
What would be the Chronic Refractory Cough total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
What are the key findings pertaining to the market across the 7MM and which country will have the largest Chronic Refractory Cough market size during the forecast period (2022-2032)?
At what CAGR, the Chronic Refractory Cough market is expected to grow at the 7MM level during the forecast period (2022-2032)?
What would be the Chronic Refractory Cough market outlook across the 7MM during the forecast period (2022-2032)?
What would be the Chronic Refractory Cough market growth till 2032 and what will be the resultant market size in the year 2032?
How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What are the disease risk, burdens, and unmet needs of Chronic Refractory Cough?
What is the historical Chronic Refractory Cough patient pool in the United States, the EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
What would be the forecasted patient pool of Chronic Refractory Cough at the 7MM level?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Chronic Refractory Cough?
Out of the above-mentioned countries, which country would have the highest incidence population of Chronic Refractory Cough during the forecast period (2022-2032)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

What are the current options for the treatment of Chronic Refractory Cough along with the approved therapy?
What are the current treatment guidelines for the treatment of Chronic Refractory Cough in the US and Europe?
What are the Chronic Refractory Cough marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
How many companies are developing therapies for the treatment of Chronic Refractory Cough?
How many emerging therapies are in the mid-stage and late stages of development for the treatment of Chronic Refractory Cough?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the Chronic Refractory Cough therapies?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Chronic Refractory Cough and their status?
What are the key designations that have been granted for the emerging therapies for Chronic Refractory Cough?
What is the 7MM historical and forecasted market for Chronic Refractory Cough?

Reasons to buy:

The report will help in developing business strategies by understanding trends shaping and driving Chronic Refractory Cough.
To understand the future market competition in the Chronic Refractory Cough market and an Insightful review of the key market drivers and barriers.
Organize sales and marketing efforts by identifying the best opportunities for Chronic Refractory Cough in the US, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
Organize sales and marketing efforts by identifying the best opportunities for the Chronic Refractory Cough market.
To understand the future market competition in the Chronic Refractory Cough market.

1. Key Insights

2. Report Introduction

3. CRC Market Overview at a Glance

3.1. Market Share (%) Distribution of CRC by therapies in 2019
3.2. Market Share (%) Distribution of CRC by therapies in 2032

4. CRC Market: Future Perspective

5. Executive Summary of CRC

6. Key Events

7. Disease Background and Overview

7.1. Introduction to CRC
7.2. Signs and Symptoms
7.3. Causes
- 7.3.1. Upper Airway Cough Syndrome (UACS)
- 7.3.2. Asthma and COPD
- 7.3.3. Non-asthmatic Eosinophilic Bronchitis
- 7.3.4. Gastroesophageal/Laryngopharyngeal Reflux Disease
7.4. Risk factors
7.5. Mechanism of CC
7.6. Pathophysiology of CC
- 7.6.1. Similarity between CRC and other neuropathic disorders
- 7.6.2. Pathogenesis of CRS
7.7. Clinical features of CRC
7.8. Diagnosis
- 7.8.1. Primary assessment
- 7.8.2. Secondary assessment
7.9. Treatment
- 7.9.1. Treatments with a Peripheral Site of Action
- 7.9.2. Treatments with a Central Site of Action
- 7.9.3. Non-pharmacologic therapies
- 7.9.4. Management of Chronic Cough
7.10. Treatment Guidelines
- 7.10.1. European Respiratory Society (ERS) guidelines on the diagnosis and treatment of CC in adults and children (2020)
- 7.10.2. Treatment of UCC American CHEST Guideline and Expert Panel Report

8. Epidemiology and Patient Population

8.1. Key Findings
8.2. Methodology of Epidemiology
8.3. Assumptions and Rationale: 7MM
- 8.3.1. 12-month Prevalent Cases of CC
- 8.3.2. Gender-specific Cases of CC
- 8.3.3. Diagnosed Prevalent Cases of CRC
- 8.3.4. Diagnosed prevalent population of CC in IPF
8.4. 12-month Prevalent Cases of CC in the 7MM
8.5. Total Diagnosed Prevalent Cases of CRC in the 7MM
8.6. The United States
- 8.6.1. 12-month Prevalent Cases of CC in the US
- 8.6.2. Gender-specific Cases of CC in the US
- 8.6.3. Total Diagnosed Prevalent Cases of CRC in the US
- 8.6.4. Diagnosed Prevalent Cases of CC in IPF in the US
8.7. The Five Major European Countries
- 8.7.1. 12-month Prevalent Cases of CC in the EU-5
- 8.7.2. Gender-specific Cases of CC in the EU-5
- 8.7.3. Total Diagnosed Prevalent Cases of CRC in the EU-5
- 8.7.4. Diagnosed Prevalent Cases of CC in IPF in the EU-5
- 8.7.5. Germany
  - 8.7.5.1. 12-month Prevalent Cases of CC in Germany
  - 8.7.5.2. Gender-specific Cases of CC in Germany
  - 8.7.5.3. Total Diagnosed Prevalent Cases of CRC in Germany
  - 8.7.5.4. Diagnosed Prevalent Cases of CC in IPF in Germany
- 8.7.6. France
  - 8.7.6.1. 12-month Prevalent Cases of CC in France
  - 8.7.6.2. Gender-specific Cases of CC in France
  - 8.7.6.3. Total Diagnosed Prevalent Cases of CRC in France
  - 8.7.6.4. Diagnosed Prevalent Cases of CC in IPF in France
- 8.7.7. Italy
  - 8.7.7.1. 12-month Prevalent Cases of CC in Italy
  - 8.7.7.2. Gender-specific Cases of CC in Italy
  - 8.7.7.3. Total Diagnosed Prevalent Cases of CRC in Italy
  - 8.7.7.4. Diagnosed Prevalent Cases of CC in IPF in Italy
- 8.7.8. Spain
  - 8.7.8.1. 12-month Prevalent Cases of CC in Spain
  - 8.7.8.2. Gender-specific Cases of CC in Spain
  - 8.7.8.3. Total Diagnosed Prevalent Cases of CRC in Spain
  - 8.7.8.4. Diagnosed Prevalent Cases of CC in IPF in Spain
- 8.7.9. The United Kingdom
  - 8.7.9.1. 12-month Prevalent Cases of CC in the UK
  - 8.7.9.2. Gender-specific Cases of CC in the UK
  - 8.7.9.3. Total Diagnosed Prevalent Cases of CRC in the UK
  - 8.7.9.4. Diagnosed Prevalent Cases of CC in IPF in the UK
8.8. Japan
- 8.8.1. 12-month Prevalent Cases of CC in Japan
- 8.8.2. Gender-specific Cases of CC in Japan
- 8.8.3. Total Diagnosed Prevalent Cases of CRC in Japan
- 8.8.4. Diagnosed Prevalent Cases of CC in IPF in Japan

9. Patient Journey

10. Emerging Drugs

10.1. Key Cross Competition
10.2. MK-7264 (gefapixant): Merck & Co/ Kyorin Pharmaceuticals
- 10.2.1. Product Description
- 10.2.2. Regulatory Milestone
- 10.2.3. Other Development Activities
- 10.2.4. Clinical Development
- 10.2.5. Clinical Trial Information
- 10.2.6. Safety and Efficacy
- 10.2.7. Product Profile
- 10.2.8. Analysts' Views
10.3. Orvepitant Maleate: NeRRe Therapeutics
- 10.3.1. Product Description
- 10.3.2. Other Development Activities
- 10.3.3. Clinical Development
- 10.3.4. Clinical Trial Information
- 10.3.5. Safety and Efficacy
- 10.3.6. Product Profile
- 10.3.7. Analysts' Views
10.4. BLU-5937: Bellus Health
- 10.4.1. Product Description
- 10.4.2. Other Development Activities
- 10.4.3. Clinical Development
- 10.4.4. Clinical Trial Information
- 10.4.5. Safety and Efficacy
- 10.4.6. Product Profile
- 10.4.7. Analysts' Views
10.5. S-600918 (sivopixant): Shionogi
- 10.5.1. Product Description
- 10.5.2. Other Development Activities
- 10.5.3. Clinical Development
- 10.5.4. Clinical Trial Information
- 10.5.5. Safety and Efficacy
- 10.5.6. Product Profile
- 10.5.7. Analysts' Views
10.6. AX-8: Axalbion
- 10.6.1. Product Description
- 10.6.2. Other Development Activities
- 10.6.3. Clinical Development
- 10.6.4. Clinical Trial Information
- 10.6.5. Safety and Efficacy
- 10.6.6. Product Profile
- 10.6.7. Analysts' Views
10.7. ADX-629: Aldeyra Therapeutics
- 10.7.1. Product Description
- 10.7.2. Clinical Development
- 10.7.3. Clinical Trial Information
- 10.7.4. Product Profile

11. CRC: The Seven Major Market Analysis

11.1. Key Findings
11.2. Methodology of CRC Market
11.3. Market Size of CRC in the 7MM
11.4. Market Size of CRC by Therapies in the 7MM
11.5. Key Market Forecast Assumptions
11.6. Attribute Analysis
11.7. Market Outlook
11.8. Market Size of CRC in the US
- 11.8.1. Total Market Size of CRC in the US
- 11.8.2. Market Size of CRC by Therapies in the US
11.9. Market Size of CRC in the EU-5
- 11.9.1. Total Market Size of CRC in the EU-5
- 11.9.2. Market Size of CRC by Therapies in the EU-5
- 11.9.3. Germany Market Size
  - 11.9.3.1. Total Market Size of CRC in Germany
  - 11.9.3.2. Market Size of CRC by Therapies in Germany
- 11.9.4. France Market Size
  - 11.9.4.1. Total Market Size of CRC in France
  - 11.9.4.2. Market Size of CRC by Therapies in France
- 11.9.5. Italy Market Size
  - 11.9.5.1. Total Market Size of CRC in Italy
  - 11.9.5.2. Market Size of CRC by Therapies in Italy
- 11.9.6. Spain Market Size
  - 11.9.6.1. Total Market Size of CRC in Spain
  - 11.9.6.2. Market Size of CRC by Therapies in Spain
- 11.9.7. The United Kingdom Market Size
  - 11.9.7.1. Total Market Size of CRC in the UK
  - 11.9.7.2. Market Size of CRC by Therapies in the UK
11.10. Market Size of CRC in Japan
- 11.10.1. Total Market Size of CRC in Japan
- 11.10.2. Market Size of CRC by Therapies

難治性慢性咳嗽市場 - 市場の洞察、疫学、市場予測：2032年

Chronic Refractory Cough - Market Insight, Epidemiology And Market Forecast - 2032

目次

第1章 主な洞察

第2章 レポートのイントロダクション

第3章 難治性慢性咳嗽市場概要

第4章 難治性慢性咳嗽市場：将来展望

第5章 難治性慢性咳嗽のエグゼクティブサマリー

第6章 主な出来事

第7章 疾患の背景と概要

第8章 疫学と患者数

第9章 患者動向

第10章 新薬

第11章 難治性慢性咳嗽：主要7ヶ国市場分析

第12章 キーオピニオンリーダーの見解

第13章 市場の促進要因

第14章 市場の抑制要因

第15章 SWOT分析

第16章 アンメットニーズ

第17章 償還と市場アクセス

第18章 付録

第19章 DelveInsightのサービス内容

第20章 免責事項

第21章 Delve Insightについて

List of Tables

List of Figures

Geography Covered:

Chronic Refractory Cough Understanding and Treatment Algorithm

Chronic Refractory Cough Epidemiology

Chronic Refractory Cough Epidemiology

Chronic Refractory Cough Drug Chapters

Chronic Refractory Cough Market Outlook

The United States Market Outlook

The EU-5 Market Outlook

Japan Market Outlook

Chronic Refractory Cough Drugs Uptake

Scope of the Report:

Report Highlights:

Chronic Refractory Cough Report Insights

Chronic Refractory Cough Report Key Strengths

Chronic Refractory Cough Report Assessment

Reasons to buy:

Table of Contents

1. Key Insights

2. Report Introduction

3. CRC Market Overview at a Glance

4. CRC Market: Future Perspective

5. Executive Summary of CRC

6. Key Events

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Emerging Drugs

11. CRC: The Seven Major Market Analysis

12. Key Opinion Leader's Views

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Reimbursement and Market Access

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About Delve Insight

第1章主な洞察

第2章レポートのイントロダクション

第3章難治性慢性咳嗽市場概要

第4章難治性慢性咳嗽市場：将来展望

第5章難治性慢性咳嗽のエグゼクティブサマリー

第6章主な出来事

第7章疾患の背景と概要

第8章疫学と患者数

第9章患者動向

第10章新薬

第11章難治性慢性咳嗽：主要7ヶ国市場分析

第12章キーオピニオンリーダーの見解

第13章市場の促進要因

第14章市場の抑制要因

第16章アンメットニーズ

第17章償還と市場アクセス

第18章付録

第20章免責事項